NewsPronto

 
The Times


.

ACN Newswire

Read more press releases from ACN Newswire here

NANOBIOTIX: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma

  • Written by ACN Newswire

image

Paris, France and Cambridge, Massachusetts, USA, Mar 24, 2017 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that the Independent Data Monitoring Committee (IDMC) has completed the interim evaluation of the...

Read more: NANOBIOTIX: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing...